Purpose One important mechanism for chemoresistance of tumours is overexpression of the adenosine triphosphatebinding cassette transporter P-glycoprotein (Pgp). Pgp reduces intracellular concentrations of chemotherapeutic drugs. The aim of this study was to compare the suitability of the radiolabelled Pgp inhibitors [ 11
Introduction
Multidrug resistance (MDR) remains a major challenge for successful systemic treatment of cancer. MDR may either be intrinsic or acquired and can be mediated by several different mechanisms including target alterations, enhanced DNA repair, evasion of apoptosis, induction of drug-metabolizing enzymes, alterations in drug uptake and active transport of drugs out of cells [1] . Energy-dependent efflux of chemotherapeutic drugs out of cells is to a great extent mediated by transmembrane transporters belonging to the adenosine triphosphate (ATP) binding cassette (ABC) superfamily, which use ATP hydrolysis as an energy source to transport a variety of structurally diverse molecules across membranes irrespective of concentration gradient [2] .
Among the 48 members of the human ABC transporter family, P-glycoprotein (Pgp, ABCB1) is the most widely studied. A multitude of studies have linked increased expression of Pgp to impaired chemotherapy response and lower patient survival [3] . For over two decades, different strategies to inhibit Pgp and to overcome MDR in cancer have been investigated but have largely been unsuccessful for several different reasons [1, 4, 5] . First-and secondgeneration Pgp inhibitors are either toxic at the concentrations needed to inhibit Pgp (verapamil, cyclosporin A, quinidine) or prone to drug-drug interactions involving cytochrome P450 inhibition (valspodar, biricodar) leading to increased systemic exposure to and hence toxicity of chemotherapeutic drugs. Third-generation Pgp inhibitors, such as tariquidar, elacridar, zosuquidar and laniquidar, are more potent and selective than earlier generation Pgp inhibitors and lack pharmacokinetic interactions, but still cause toxicities in cancer patients and fail to improve patient survival which has resulted in early closure of several clinical trials [4, 5] .
A substantial limitation of most clinical trials with Pgp inhibitors is that Pgp expression in tumours of the study participants has not been assessed, which is not surprising given the invasive nature of biopsies and the lack of alternative methodology. To improve future clinical trials with Pgp inhibitors, a noninvasive molecular imaging protocol, which is able to assess Pgp expression and/or function, might be very useful in selecting patients whose cancer is likely to be chemoresistant through a Pgpmediated mechanism [6] . One of the most widely used imaging agents to assess Pgp function is the single-photon emission computed tomography (SPECT) tracer [ 99m Tc] sestamibi, which is a substrate of both Pgp and multidrug resistance protein 1 (MRP1, ABCC1) [7] . In some clinical trials with Pgp inhibitors, imaging of [ 99m Tc]sestamibi uptake has been used as a surrogate marker for tumoral Pgp inhibition [8] [9] [10] . However, [ 99m Tc]sestamibi is not an ideal Pgp imaging agent as it is not selective for Pgp and shows very low retention in Pgp-expressing tumours due to rapid washout [7] .
An imaging probe for the highly sensitive and quantitative imaging method positron emission tomography (PET) would be preferred over a SPECT imaging agent to accurately and noninvasively measure Pgp in tumours. [15] [16] [17] was evaluated as reference radiotracer in the same model.
Materials and methods

Materials
All chemicals were purchased from Sigma-Aldrich Chemie (Schnelldorf, Germany) or Merck (Darmstadt, Germany), and were of analytical grade and used without further purification. Waymouth's MB 752/1, RPMI and heat-inactivated fetal bovine serum (FBS) were purchased from GIBCO (Invitrogen, Lofer, Austria). Penicillin/streptomycin solution was purchased from PAA Laboratories (Pasching, Austria). Doxorubicin hydrochloride was dissolved in sterile water at a concentration of 5 mg/ml, stored as aliquots at −30°C and diluted immediately prior to use. PhosSTOP tablets and cOmplete Protease Inhibitor cocktail were obtained from Roche Diagnostics (Mannheim, Germany). The anti-Pgp primary antibodies C219 and H241 were obtained from Signet (Dedham, MA) and from Santa Cruz Biotechnology (Santa Cruz, CA), respectively. The breast cancer resistance protein (BCRP, ABCG2) primary antibody BXP-53, which recognizes an internal epitope in murine Bcrp1 and human BCRP, was purchased from Abcam (Cambridge, UK). Anti-actin primary antibody was purchased from Sigma (Saint Louis, MO EMT6 cells were cultured as monolayers in Waymouth's MB 752/1 medium supplemented with 2.4 mM of Lglutamine, 15% heat-inactivated FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. The Pgp-overexpressing EMT6Ar1.0 cell line was derived by in vitro culture of EMT6 cells in the presence of increasing concentrations of doxorubicin as described previously [18] . JC and NCI/ADRRes cells were cultured according to the supplier's instructions. BCRP-overexpressing MCF7AdVp3000 cells were maintained in RPMI-1640 medium containing 10% heatinactivated FBS supplemented with 3,000 ng/ml doxorubicin and 5 μg/ml verapamil.
Western blotting
Cells (2×10 5 ) were cultured in six-well plates for 48 h and whole cell extracts were prepared. Snap-frozen tumour grafts were pulverized using a MM200 mixer mill (Retsch, Haan, Germany) and proteins were extracted. Total protein at 15-20 μg per lane was loaded onto a 10-13% SDSpolyacrylamide gel and blotted on a PVDF membrane (Millipore, Billerica, MA). The membranes were blocked for 1 h, and then incubated with the primary antibodies (C219 1:100, BXP-53 1:100, anti-actin 1:5,000) at 4°C overnight. Subsequently, the membranes were washed and incubated with the secondary antibodies (dilution 1:4,000). The bound antibody was detected by chemiluminescence using enhanced luminol-based chemiluminescent reagents (Pierce, Rockford, IL) and exposure of the membranes to chemiluminescence hyperfilms (GE Healthcare, Piscataway, NJ). Human breast carcinoma whole-cell lysate ZR-75-1 (Santa Cruz, CA) was used as control to confirm the identity of the signals, JC cells were used as control for the protein extraction procedure as JC cells express Pgp in vitro [19] . BCRP-expressing MCF7AdVp3000 cells were used as positive control for Bcrp1 [20] . Expression of β-actin was measured to confirm consistent gel loading.
Immunocytochemistry
Immunocytochemical detection of Pgp on tumour cells cultivated on chamber slides was performed using rabbit polyclonal antibody H241. Experimental details are given in the Electronic Supplementary Material.
In vitro cytotoxicity assay EMT6 and EMT6Ar1.0 cells were treated in vitro with increasing concentrations of tariquidar in their respective culture media and cell survival was measured. Experimental details are given in the Electronic Supplementary Material.
Animals
Female athymic nude NMRI-Foxn1 nu mice (Taconic, Ry, Denmark) aged 6-8 weeks, weighing 25-30 g, were housed in Makrolon type 2 filter-top cages (three or four mice per cage) under controlled environmental conditions (24±2°C, 40-70% humidity, 12-h light/dark cycle). An acclimatization period of >1 week was allowed before the animals were used in the experiments. EMT6 and EMT6Ar1.0 cells were harvested and resuspended in PBS, and 3-5×10 5 cells were subcutaneously injected into the left and right upper flank, respectively. When tumours had grown to a size of approximately 130 mm 3 , the animals underwent PET imaging. The study was approved by the local animal welfare committee and all study procedures were performed in accordance with the Austrian Animal Experiments Act.
Tracer synthesis and formulation ]verapamil were synthesized as described previously [13, 14, 16] . For intravenous (i.v.) injection into animals, each radiotracer was formulated in 0.9% aqueous saline containing 75 μl Tween 80 to an approximate concentration of 370 MBq/ml. Radiochemical purity, as determined by radio-HPLC, was greater than 98%, and specific activity at the end of synthesis was >100 GBq/μmol. [ 
Small-animal PET
Prior to each experiment, the animals were placed in an induction box and anaesthetized with 2.5% isoflurane. During the imaging period anaesthesia was maintained with 1-2% isoflurane administered via a cone mask and the isoflurane level was adjusted depending on the depth of anaesthesia. The respiratory rate and body temperature of the animals were constantly monitored during the data acquisition period. The animals were kept warm throughout the experiment at approximately 37°C. The animals were positioned in a custom-made imaging chamber and a lateral tail vein was cannulated for radiotracer administration.
For PET imaging a microPET Focus220 scanner (Siemens Medical Solutions, Knoxville, TN) was used. The animals were divided into three groups. Animals of group 1 (n = 7), group 2 (n = 6) and group 3 (n =7) underwent two consecutive dynamic PET scans with [
11 C] tariquidar (injected activity 40±8 MBq), [ 11 C]elacridar (injected activity 39±10 MBq), and (R)-[
11 C]verapamil (injected activity 39±4 MBq), respectively (Fig. 1) . Scan 1 (150 min), during which unlabelled tariquidar (15 mg/kg) was injected i.v. 60 min after radiotracer injection, was followed by scan 2 (60 min), which was recorded at 120 min after unlabelled tariquidar administration [13, 14] . At the end of scan 2, a 20-min static [ MBq) . For all groups, list-mode data were acquired for the defined time period with an energy window of 250-750 keV and a 6-ns timing window. Before each PET scan, a transmission scan using a 57 Co point source was recorded for 10 min.
After completion of the imaging procedure, animals were killed by cervical dislocation while still under deep anaesthesia. Tumours were excised and either snap-frozen in liquid nitrogen or embedded in freezing medium (Tissue-Tek, Sakura, The Netherlands) and frozen in isopentane (−70°C). Samples were stored at −80°C until further processing.
In vitro autoradiography
Tumours were cut into 10-μm slices using a cryostat (Microm HM550, Walldorf, Germany) at −12°C. Consecutive tumour sections (n=3) were mounted on SuperFrost Plus slides (Menzel, Braunschweig, Germany), air-dried and stored at −30°C. On the day of the experiment, the slides were thawed and preincubated in PBS. Tumour slices were then incubated for 30 min with either radiotracer alone (about 20 MBq) or radiotracer with unlabelled tariquidar (10 μM) or unlabelled elacridar (10 μM). In the case of (R)-[
11 C]verapamil one set of slides was additionally treated with unlabelled racemic verapamil (10 μM). To remove radiotracer that was not specifically bound, slides were then washed with 20% (v/v) ethanol in PBS and distilled water. The slides were air-dried and exposed to a multisensitive phosphor screen (Perkin-Elmer Life Sciences, Waltham, MA). The screens were removed from the film cassettes under dim light conditions and immediately scanned at 600 dpi resolution using a Cyclone storage phosphor system (Perkin-Elmer Life Sciences). Images were analysed using the system's Optiquant v5.0 software. Tumour ROIs were outlined, for which the backgroundcorrected digital luminescence units per millimetre squared were calculated.
PET data analysis
The dynamic PET data were sorted into three-dimensional sinograms. Images were reconstructed using Fourier rebinning of the 3-D sinograms followed by two-dimensional filtered back-projection. The standard data correction protocol (normalization, decay correction and injection decay correction) was applied to the data. Tumour ROIs were manually outlined over multiple planes in the static [ 
Statistical analysis
Differences in tumour and brain AUC 0-60 values between scan 1 and scan 2 were analysed by a two-sided Wilcoxon matched pairs signed ranks test using PRISM 5 software (GraphPad Software, La Jolla, CA). The level of statistical significance was set to p<0.05.
Results
Pgp overexpression
In vitro, parental EMT6 cells showed only very low Pgp expression, whereas a dose-dependent increase in Pgp expression was observed following exposure of cells to increasing concentrations of doxorubicin (Fig. 2a) . Western blotting of excised tumours (Fig. 2b) confirmed that Pgp overexpression observed in EMT6Ar1.0 cell lysates was maintained in vivo. However, as compared to the corresponding cell lysates (Fig. 2a) , differences in Pgp expression between EMT6Ar1.0 and EMT6 tumours appeared to be smaller (Fig. 2b) . Because tariquidar and elacridar are known to interact with BCRP, we also investigated Bcrp1 expression levels of cell lysates and tumours. Only basal levels of Bcrp1 expression could be detected in EMT6 cells which were not different from the doxorubicin-exposed EMT6Ar1.0 cells (Fig. 2c) . Also in vivo, comparably low Bcrp1 expression levels were detected in EMT6 and EMT6Ar1.0 tumours (Fig. 2d) . Immunocytochemical detection of Pgp is shown in Fig. S1 (Electronic Supplementary Material). In EMT6 cells only weak Pgp staining, mostly in intracellular vesicles, was observed (Fig. S1a) . In EMT6Ar1.0 cells an overall much more intensive staining for Pgp was detected, mainly at the plasma membrane, with a variable degree of staining intensity between individual cells (Fig. S1c) . Fig. 1 , a diagram of the study set-up is shown. Figure 3 shows representative PET summation images before and 2 h after tariquidar administration for all three radiotracers and corresponding [ (Fig. 5c ) the differences in AUCs 0-60 between tumours were not statistically significant. In response to tariquidar administration during scan 1, TACs of all three radiotracers showed modest increases in both EMT6Ar1.0 and EMT6 tumours (Fig. 4) . In the brain, which was assessed as a reference region for Pgp modulation at the BBB, tariquidar-induced increases in activity uptake during scan 1 were more pronounced than in tumours for all three radiotracers (Figs. 4 and 5) . For all radiotracers, tumour activity levels were two to three times higher than brain activity levels in scan 1.
In scan 2, which was recorded 2 h after tariquidar administration, tumour AUC 0-60 values were increased (range 9-30%) relative to those in scan 1 in both EMT6Ar1.0 and EMT6 tumours for all three radiotracers, although none of these increases reached statistical significance (Fig. 5) . Moreover, AUC 0-60 increases in scan 2 were not significantly different between EMT6Ar1.0 and EMT6 ]tariquidar, activity levels in the brain were higher in scan 2 than tumour activity levels.
In Fig. S3 (Fig. 6b, d ). Binding of (R)- [ 11 C]verapamil in EMT6Ar1.0 tumours was only 1.3 times higher than in EMT6 tumours with no significant reduction in either tumour after coincubation with unlabelled tariquidar, elacridar or verapamil (Fig. 6e) .
Discussion
The aim of this study was to compare the suitability of [ 11 C]verapamil, a commonly used radiotracer for assessing Pgp function [15] [16] [17] , to discriminate Pgp-positive from Pgp-negative tumours using small-animal PET. We found that [ Tariquidar and elacridar are potent noncompetitive inhibitors of Pgp, which inhibit ATPase activity, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both [4] [23] ) to provide a Pgp-specific binding signal with these radiotracers.
In the present study, tumour activity uptake of [ and resistant to doxorubicin were derived from the same cell line and implanted bilaterally into the animals, so that each animal served as its own control. A possible limitation of the employed model may be that tumours were derived from a murine and not from a human cell line, which could limit the extrapolation of the results to human tumours. Moreover, the possibility that Pgp expression levels of murine EMT6Ar1.0 tumours are different from (i.e. higher than) those in clinical tumour samples cannot be excluded. [ (Fig. 5a ). The Pgp substrate (R)-[ 11 C] verapamil, on the other hand, showed lower (although not statistically significant) retention in EMT6Ar1.0 than in EMT6 tumours (Fig. 5c) , which points to Pgp-mediated efflux transport of (R) (Fig. S3) . Similar results have been obtained in a previous study [24] and may be explained by higher glucose consumption due to increased basal ATPase activity or increased blood flow or anaerobic metabolism in EMT6Ar1.0 tumours.
To assess the Pgp specificity of the PET signal, we performed PET scans in mice before, during and after administration of unlabelled tariquidar (Fig. 1) , an approach already used in previous studies for assessment of Pgpspecific binding of [ 11 C]tariquidar and [ 11 C]elacridar at the rodent BBB [13, 14] . The tariquidar dose used (15 mg/kg) has been reported to result in complete inhibition of Pgp at the BBB [17] . Due to the long terminal elimination half-life of tariquidar (26 h) [4] , it could be expected that plasma levels of tariquidar were stable during scan 2. We observed changes in the tumour PET signal following unlabelled tariquidar administration (Fig. 5) (Fig. 6b, d ).
These apparently contradictory observations might be explained by additional, competing transport mechanisms only present in the in vivo model such as inhibition of efflux transport of [ 11 ]elacridar from their Pgp-binding sites and at the same time increased tumour cellular uptake by inhibition of Pgp/BCRP-mediated efflux transport of radiotracer. In line with this assumption, Western blot analysis showed that both EMT6Ar1.0 and EMT6 tumours had basal Bcrp1 expression levels (Fig. 2c, d) . In contrast to tumours, the substrate properties of [ C]elacridar seem to prevail at the BBB with its lower Pgp expression, resulting in more pronounced increases in activity uptake following tariquidar challenge in brain than in tumours (Fig. 4) . A third mechanism which might play a role in tumour retention of [ [11] , which are extensively metabolized in vivo, possibly resulting in tumour accumulation of radiolabelled metabolites.
Conclusion
Even though its tumour retention mechanisms appear to be complex, [ 11 C]tariquidar merits further investigation as a PET tracer to assess Pgp expression levels of solid tumours. As tariquidar is one of a few Pgp inhibitors which is still being tested in clinical trials [4] , the use of [ 11 C]tariquidar PET to preselect patients with high Pgp expression levels for cotreatment with tariquidar is a promising personalized medicine approach in cancer therapy. Besides its potential utility as a PET tracer, radiolabelled tariquidar might be useful for quantifying Pgp expression levels in vitro.
